TY  - JOUR
AU  - Spencer, D.A.
AU  - Auffinger, B.M.
AU  - Murphy, J.P.
AU  - Muroski, M.E.
AU  - Qiao, J.
AU  - Gorind, Y.
AU  - Lesniak, M.S.
PY  - 2017//
TI  - Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
T2  - Curr Cancer Drug Targets
JO  - Current Cancer Drug Targets
SP  - 236
EP  - 254
VL  - 17
IS  - 3
KW  - Brain Neoplasms/drug therapy/pathology
KW  - Drug Resistance
KW  - Neoplasm/drug effects
KW  - Glioblastoma/*drug therapy/pathology
KW  - Glioma/drug therapy/*pathology
KW  - Humans
KW  - Molecular Targeted Therapy/*methods
KW  - Neoplastic Stem Cells/drug effects/*pathology/radiation effects
KW  - Chemotherapy
KW  - drug targets
KW  - glioblastoma multiforme
KW  - glioma stem cells
KW  - niches
KW  - recurrence
KW  - resistance
AB  - BACKGROUND: Glioblastoma multiforme (GBM) continues to devastate patients and outfox investigators and clinicians despite the preponderance of research directed at its biology, pathogenesis and therapeutic advances. GBM routinely outlasts multidisciplinary treatment protocols, almost inevitably recurring in a yet more aggressive and resistant form with distinct genetic differences from the original tumor. Attempts to glean further insight into GBM point increasingly toward a subpopulation of cells with a stem-like phenotype. These cancer stem cells, similar to those now described in a variety of malignancies, are capable of tumorigenesis from a population of susceptible cells. CONCLUSIONS: Glioma stem cells have thus become a prevalent focus in GBM research for their presumed role in development, maintenance and recurrence of tumors. Glioma stem cells infiltrate the white matter surrounding tumors and often evade resection. They are uniquely suited both biochemically and environmentally to resist the best therapy currently available, intrinsically and efficiently resistant to standard chemo- and radiotherapy. These stem cells create an extremely heterogenous tumor that to date has had an answer for every therapeutic question, with continued dismal patient survival. Targeting this population of glioma stem cells may hold the long-awaited key to durable therapeutic efficacy in GBM.
SN  - 1568-0096
UR  - http://www.ncbi.nlm.nih.gov/pubmed/27993114
UR  - PM:27993114
N1  - PMID:27993114
ID  - Spencer_etal2017
ER  -